Vertex Pharma Stock Surges After FDA Approves Non-Opioid Pain Drug
Analyst is bullish on Vertex Pharmaceuticals, citing FDA approval for JOURNAVX and strong earnings growth potential in 2025.
Vertex Pharmaceuticals Stock Jumps as Non-Opioid Painkiller Gets FDA Approval
Key Takeaways Vertex Pharmaceuticals' non-opioid painkiller received approval from the Food and Drug Administration.The drugmaker said the twice-daily pill, Journavx, is the first such treatment to ...
BioSpace11h
FDA Approves Vertex’s Journavx as First New Pain Drug in Decades
The greenlight for Journavx (suzetrigine), which comes on the heels of a $7.4 billion opioid settlement, could spark momentum ...
Vertex Pharmaceuticals price target raised to $435 from $418 at Barclays
Barclays analyst Gena Wang raised the firm’s price target on Vertex Pharmaceuticals (VRTX) to $435 from $418 and keeps an Equal Weight rating ...
FDA approves new pain drug Journavx as opioid alternative
Federal officials on Thursday approved a new type of pain drug designed to eliminate the risks of addiction and overdose ...
Benzinga.com17d
Vertex Pharmaceuticals Sets Sight on Expanding Portfolio with Alyftrek Approval, Pain Treatment Progress, and Diabetes Trials
Get Wall Street's Hottest Chart Every Morning RBC Capital Markets says Vertex management is optimistic about the recently approved Alyftrek. They predict that most of the 6,000 patients who ...